Format

Send to

Choose Destination
See comment in PubMed Commons below
J Endocrinol Invest. 2013 Feb;36(2):140-5.

Thyroid safety in patients treated with liraglutide.

Author information

1
Oncological Endocrinology, AO Citta' della Salute e della Scienza-Molinette, Via Genova, 3, I-10137 Turin, Italy. mgallo4@cittadellasalute.to.it

Abstract

During the last years, various novel anti-diabetic drugs have considerably enriched the therapeutic armamentarium for subjects with Type 2 diabetes. In the meantime, much interest has recently been focused on the potential cardiovascular and oncological adverse effects of these new therapies. As to glucagon-like peptide 1 (GLP-1) analogs, medullary thyroid tumors were reported to be more common in rodent toxicology studies with liraglutide, although the relevance of this finding in humans has been questioned. Analyses of sequential changes in calcitonin levels in several thousands of subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin. Furthermore, no medullary thyroid cancer has been detected in humans taking liraglutide. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and deserve further investigation.

PMID:
23481614
DOI:
10.1007/BF03346749
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center